Ardelyx, Inc. (ARDX)
ARDX moved a median of -0.09% 30 minutes after news, and +0.13% by the close. How ARDX actually reacts to news — the realized, point-in-time move the market made, measured across 1,024 labeled events over the last three years with zero look-ahead.
ARDX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 1,016 |
| 30-min | -0.09% | 47% | 1,016 |
| 60-min | 0.00% | 49% | 1,016 |
| to close | +0.13% | 51% | 1,015 |
| Middle 50% of ARDX reactions | -0.91% to +0.82% |
|---|---|
| Median reaction (30-min) | -0.09% |
| Measured reactions | 1,024 |
Half of all Ardelyx, Inc. news events land between -0.91% and +0.82% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ARDX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +1.29% | 55% | +0.18% |
| Analyst downgrades | 14 | +0.83% | 64% | +0.54% |
| Coverage initiations | 17 | +1.15% | 88% | +1.01% |
| Rating reiterations | 80 | -0.09% | 46% | -0.14% |
| Price-target raises | 17 | +0.17% | 59% | +0.79% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how ARDX ranks against every other measured name →
That’s how ARDX usually reacts — get an email when it moves on news →Email me when ARDX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARDX's baseline. Nothing else.
Recent ARDX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX | Press release | PR Newswire | -1.29% | +2.90% | |
| Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C | Press release | GlobeNewswire | -1.22% | -1.52% | |
| Kaplan Fox Encourages Ardelyx, Inc. (NASDAQ:ARDX) Investors Seeking Recovery to Contact the Firm Before November 16, 2026 | Press release | ACCESS Newswire | -0.46% | +0.61% | |
| Kaplan Fox Encourages Ardelyx, Inc. (NASDAQ:ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026 | Press release | ACCESS Newswire | -1.07% | +0.00% | |
| Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 | Press release | GlobeNewswire | +0.15% | +1.19% | |
| Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards | Press release | GlobeNewswire | -0.73% | -0.29% | |
| Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX | Press release | Business Wire | -0.44% | +2.04% | |
| Ardelyx to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.27% | -0.53% | |
| Form 8-K ARDELYX, INC. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | -3.21% | |
| Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -3.06% | -1.96% | |
| Form 10-Q ARDELYX, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.06% | -1.96% | |
| Form 8-K ARDELYX, INC. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -3.06% | -1.96% | |
| Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | GlobeNewswire | +0.40% | +2.60% | |
| Form 8-K ARDELYX, INC. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +0.96% | +2.69% | |
| Form 8-K ARDELYX, INC. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -0.85% | +2.54% | |
| Form DEFA14A ARDELYX, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.95% | -2.37% | |
| Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 | Press release | GlobeNewswire | -0.90% | -0.49% | |
| Form DEFA14A ARDELYX, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +1.40% | +3.46% | |
| Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings | Press release | GlobeNewswire | +0.43% | -0.85% | |
| Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.17% | +14.67% | |
| Form 10-Q ARDELYX, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.17% | +14.67% | |
| Form 8-K ARDELYX, INC. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +2.17% | +14.67% | |
| Form ARS ARDELYX, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.06% | +4.28% | |
| Form DEF 14A ARDELYX, INC. For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | +2.06% | +4.28% | |
| Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings | Press release | GlobeNewswire | +1.01% | +1.01% | |
| Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 | Press release | GlobeNewswire | +1.16% | -1.16% | |
| Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer | Press release | GlobeNewswire | +1.36% | -1.56% | |
| Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026 | Press release | GlobeNewswire | +0.08% | +0.72% | |
| Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx | Press release | GlobeNewswire | +0.74% | +0.49% | |
| Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award | Press release | GlobeNewswire | -0.64% | -4.07% | |
| Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C | Press release | GlobeNewswire | -1.43% | -2.86% | |
| Ardelyx to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.38% | +5.56% | |
| Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions | Press release | GlobeNewswire | -1.13% | +5.64% | |
| Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -4.78% | -11.71% | |
| Form 10-K ARDELYX, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.78% | -11.71% | |
| Form 8-K ARDELYX, INC. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -4.78% | -11.71% | |
| Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 | Press release | GlobeNewswire | +0.48% | -3.58% | |
| Ardelyx Receives New Patent for Tenapanor | Press release | GlobeNewswire | +0.64% | -1.40% | |
| First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA | Press release | GlobeNewswire | -0.26% | +0.26% | |
| Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets | Press release | PR Newswire | +1.08% | -0.45% | |
| Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook | Press release | GlobeNewswire | +6.62% | +14.38% | |
| Form 8-K ARDELYX, INC. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +6.62% | +14.38% | |
| Form 8-K ARDELYX, INC. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | -1.90% | |
| Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week | Press release | GlobeNewswire | -0.17% | -0.88% | |
| Ardelyx to Participate at the Jefferies Global Healthcare Conference in London | Press release | GlobeNewswire | +1.60% | +6.06% | |
| Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference | Press release | GlobeNewswire | +0.00% | -4.92% | |
| Form S-3ASR ARDELYX, INC. | SEC filing · Form S-3ASR | SEC EDGAR | +0.00% | -4.92% | |
| Form S-8 ARDELYX, INC. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -4.92% | |
| Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -7.00% | -5.75% | |
| Form 10-Q ARDELYX, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.00% | -5.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARDX section they belong to.
Where else ARDX is measured.
ARDX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Savara, Inc. (SVRA) | 1,030 | 0.00% | 46% |
| INTREXON CORP (XON) | 1,025 | +0.05% | 52% |
| Baxter International Inc. (BAX) | 1,022 | -0.15% | 42% |
| ENDOLOGIX (ELGX) | 1,019 | -0.07% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ardelyx, Inc.'s median reaction calculated?
Every labeled ARDX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,024 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of ARDX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARDX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.